Development and characterization of an interleukin-2-transduced human ovarian carcinoma tumor vaccine not expressing major histocompatibility complex molecules

American Journal of Obstetrics and Gynecology

Volumn 174, Issue 2, 1996, Pages 633-640

  Santin, A D ^a   Ioli, G R ^a   Hiserodt, J C ^a   Manetta, A ^a   Pecorelli, S ^a   DiSaia, P J ^a   Granger, G A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Interleukin 2; ovarian cancer; tumor vaccine

Indexed keywords

CANCER VACCINE; INTERLEUKIN 2;

ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL CLONE; CYTOPATHOGENIC EFFECT; HUMAN; HUMAN CELL; IMMUNOGENICITY; OVARY CARCINOMA; PRIORITY JOURNAL; VACCINE PRODUCTION;

EID: 0030028512     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9378(96)70441-6     Document Type: Article

References (20)

1. PJ DiSaia WT. Creasman Epithelial ovarian cancer PJ DiSaia WT Creasman Clinical gynecologic oncology 1993 Mosby - Year Book St. Louis 333 425
2. HB Hewitt ER Blake AS. Walder A critique of the evidence for active host defence against cancer, based on personal studies of 27 murine tumors of spontaneous origin Br J Cancer 33 1976 241 259
3. JL Maryanski P Pala J Corradin BB Jordan JC. Cerrotini H-2-restricted cytolytic T-cells specific for HLA can recognize a synthetic HLA peptide Nature 324 1986 578 579
4. d by cytolytic T-cells Cell 58 1989 293 303
5. F Cavallo F Di Pierro Giovarelli Protective and curative potential of vaccination with interleukin-2-gene-transfected cells from a spontaneous mouse mammary adenocarcinoma Cancer Res 53 1993 5067 5070
6. ER Fearon DM Pardoll T Itaya Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response Cell 60 1990 397 403
7. + T-lymphocytes in the primary and memory response to non-immunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene J Immunol 149 1992 3627 3635
8. J Connor R Bannerji S Saito W Heston W Fair E. Gilboa Regression of bladder tumors in mice treated with interleukin 2 gene-modified tumor cells J Exp Med 177 1993 1127 1134
9. KA. Smith Cytokines in the nineties Eur Cytokine Netw 1 1990 7 13
10. V Colizzi In vivo and in vitro administration of interleukin-2 containing preparations reverses T-cells unresponsiveness in Mycobacterium bovis BCG-infected mice Infect Immunol 45 1984 25 28
11. M Malkovsky PB Medawar DR Thatcher Acquired immunological tolerance of foreign cells is impaired by recombinant interleukin-2 or vitamin A acetate Proc Natl Acad Sci U S A 83 1985 536 538
12. V Colizzi M Malkvosky G Lang GL. Asherson In vivo activity of interleukin-2: conversion of a stimulus causing unresponsiveness to a stimulus causing contact hypersensitivity by injection of interleukin-2 Immunology 56 1985 653 658
13. Gamboa-Vujicic G, Iravani L, Bhaumik M, et al. Characterization and development of UCI107: a primary human ovarian carcinoma cell line. Gynecol Oncol [In press].
14. AD Miller GJ. Rosman Improved retroviral vectors for gene transfer and expression Biotechniques 7 1989 980 990
15. S Gillis KA. Smith A long term culture of tumor-specific cytotoxic T cells [Letter] Nature 268 1977 154 156
16. WM. Strauss Preparation of genomic DNA from mammalian tissue FM Ausubel R Brent RE Kingstone Current protocols in molecular biology 1 1988 John Wiley New York 2.2.1 223
17. S Tabor K. Struhl FM Ausubel R Brent RE Kingstone Labeling of DNA by random oligonucleotide-primed synthesis 1 1988 John Wiley New York 3.5.9 3510
18. RS Yamamoto CF Ware GA Granger The human LT system, XI: identification of LT and ”TNF-like” forms from stimulated natural killers, specific and non-specific cytotoxic human T-cells in vitro J Immunol 137 1986 1878 1884
19. + tumor-infiltrating lymphocytes in human renal cell carcinoma Cancer Res 50 1990 2363 2370
20. SA Rosenberg MT Lotze LM Muul A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high doses interleukin-2 alone N Engl J Med 316 1987 889 897